Format

Send to

Choose Destination
See comment in PubMed Commons below
J Thorac Dis. 2013 Apr;5(2):145-8. doi: 10.3978/j.issn.2072-1439.2013.03.03.

The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.

Author information

1
Departments of Respiratory Medicine, Juntendo University, Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan;

Abstract

BACKGROUND:

Although N-ERC/mesothelin (N-ERC) is an attractive diagnostic and treatment monitoring biomarker for malignant pleural mesothelioma (MPM), its clinical utility for predicting the prognosis has not yet been clarified. The aim of this study is to investigate whether the serum N-ERC level can accurately predict the outcome in patients with MPM.

METHODS:

Twenty-six patients with MPM were enrolled. Serum N-ERC level was measured before and after chemotherapy. The N-ERC index was determined by the logarithm of the division of the N-ERC level after two courses of chemotherapy by the prior level.

RESULTS:

The median N-ERC index in the partial response (PR) group was significantly lower than that in patients with the stable disease (SD) plus the progressive disease (PD) group. The overall survival in the group whose median N-ERC index was lower than its median value was significantly longer than the group whose median N-ERC index was higher than its median value.

CONCLUSIONS:

The N-ERC index is therefore considered to be a useful biomarker for predicting not only the chemotherapeutic response, but also the prognosis in patients with advanced MPM.

KEYWORDS:

Mesothelioma; N-ERC index; biomarker; prognosis; response

PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for AME Publishing Company Icon for PubMed Central
    Loading ...
    Support Center